Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 18/20 | 1.00 |
| ▸ | PPARA | Q07869 | 2/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.56 |
| ▸ | RARG | P13631 | 1/20 | 0.56 |
| ▸ | FFAR1 | O14842 | 3/20 | 0.50 |
| ▸ | MPC2 | O95563 | 1/20 | 0.49 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lobeglitazone SCHEMBL20125583 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL20125580 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL2742697 | 1.00 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| Lobeglitazone SCHEMBL29778221 | 0.97 | PPARG (1.00) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884045 | 0.93 | PPARG (0.86) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL19454945 | 0.92 | PPARG (0.85) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883617 | 0.86 | PPARG (0.75) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5884168 | 0.85 | PPARG (0.74) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883649 | 0.84 | PPARG (0.73) | PPARGPPARARXRARARGFFAR1 | |
| SCHEMBL5883494 | 0.82 | PPARG (0.69) | PPARGPPARARXRARARGFFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1089 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4731202-A1 | METHODS FOR MEASURING METABOLIC DYSFUNCTION OR RISK OR PRESENCE OF AN AGE-ASSOCIATED DISEASE | Loyal Animal Health, Inc. (US) | 2026-04-29 | — | — | EP | claimed |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | ESCIENT PHARMACEUTICALS INC (US) | 2026-04-23 | — | — | US | claimed |
| EP-4725479-A1 | PPAR AGONISTS FOR TREATMENT OF DISEASES ASSOCIATED WITH AATD | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2026-04-15 | — | — | EP | claimed |
| US-20250360215-A1 | PHARMACEUTICAL COMBINATIONS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE DISEASES | YUH CHIOU HWA (US) | 2025-11-27 | — | — | US | claimed |
| US-20250332101-A1 | Composition | CORDEIRO MARIA FRANCESCA (GB) | 2025-10-30 | — | — | US | claimed |
| EP-4640701-A2 | GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF | Janssen Sciences Ireland Unlimited Company (IE) | 2025-10-29 | — | — | EP | claimed |
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | THE RESEARCH INSTITUTE AT NATIONWIDE CHILDREN’S HOSPITAL | 2025-09-11 | — | — | US | claimed |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | ACLIPSE TWO INC. | 2025-08-21 | — | — | US | claimed |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD (IL) | 2025-07-10 | — | — | US | claimed |
| WO-2025136060-A1 | CULTURE MEDIUM COMPOSITION FOR TRANSDIFFERENTIATION OF MUSCLE STEM CELLS INTO ADIPOCYTES, AND METHOD FOR PRODUCING CULTURED MEAT BY USING SAME | 한화솔루션 주식회사 | 2025-06-26 | — | — | WO | claimed |
| CN-114630681-A | Treatment of liver diseases or disorders comprising ACTRII receptor antagonists | 诺华股份有限公司 | 2022-06-14 | — | — | CN | claimed |
| US-20220170034-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | INARI AGRICULTURE TECHNOLOGY, INC. | 2022-06-02 | — | — | US | claimed |
| EP-3999103-A1 | IMPROVED HOMOLOGY DEPENDENT REPAIR GENOME EDITING | Inari Agriculture, Inc. (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3988123-A1 | ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS | Janssen Pharmaceutica NV (BE) | 2022-04-27 | — | — | EP | claimed |
| WO-2022081350-A2 | METHODS FOR IDENTIFICATION, STRATIFICATION, AND TREATMENT OF CNS DISEASES | DUKE UNIVERSITY (US) | 2022-04-21 | — | — | WO | claimed |
| CN-114340632-A | Pharmaceutical composition for treating or preventing nonalcoholic steatohepatitis (NASH) | 赛特瑞恩股份有限公司 | 2022-04-12 | — | — | CN | claimed |
| US-20220096435-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | TICURE LTD. (IL) | 2022-03-31 | — | — | US | claimed |
| WO-2022029334-A1 | COMBINATION THERAPIES FOR TREATING CORONAVIRUS INFECTION | GBIOTECH S.À.R.L. (CH) | 2022-02-10 | — | — | WO | claimed |
| WO-2022020967-A1 | USE OF WNT/BETA-CATENIN PATHWAY INHIBITORS TO BLOCK REPLICATION OF SARS-COV-2 AND OTHER PATHOGENIC VIRUSES | THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) | 2022-02-03 | — | — | WO | claimed |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | TICURE LTD. (IL) | 2022-01-25 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281507-A1 | METHODS OF TREATING NEPHROTIC SYNDROME | PPARA, PPARG, PPARD | PPARG 2/4885PPARA 1/4885RXRA 60/4885 |
| US-20220096435-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | PPARG 46/4885PPARA 50/4885RXRA 70/4885 |
| US-20260108482-A1 | MODULATORS OF MAS-RELATED G-PROTEIN RECEPTOR X4 AND RELATED PRODUCTS AND METHODS | MRGPRX4, MRGPRX1, MRGPRX2 | PPARG 467/4885PPARA 1336/4885RXRA 159/4885 |
| US-20250262209-A1 | TREATMENT OF GASTROINTESTINAL DISEASES | FABP6, SLC10A2, FABP2 | PPARG 17/4885PPARA 40/4885RXRA 275/4885 |
| US-20250221962-A1 | FABP4 AS A THERAPEUTIC TARGET IN SKIN DISEASES | FABP4, FABP2, FABP1 | PPARG 46/4885PPARA 50/4885RXRA 70/4885 |
| US-11229624-B2 | FABP4 as a therapeutic target in skin diseases | FABP4, FABP2, FABP1 | PPARG 46/4885PPARA 50/4885RXRA 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.